Related Experiment Video

Updated: Jul 15, 2025

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

15.8K

The Impact of RSV Hospitalization on Children's Quality of Life

August Wrotek1,2, Oliwia Wrotek3, Teresa Jackowska1,2

  • 1Department of Pediatrics, Centre of Postgraduate Medical Education, 99/103 Marymoncka Str., 01-813 Warsaw, Poland.

Diseases (Basel, Switzerland)
|September 27, 2023
PubMed

Insights

Respiratory syncytial virus (RSV) significantly impacts children's quality of life (QoL) during hospitalization. This study quanties RSV's effect on utility and quality-adjusted life years (QALY) loss in young children.

Area of Science:

  • Pediatric Infectious Diseases
  • Health Economics
  • Quality of Life Research

Background:

  • Respiratory syncytial virus (RSV) is a primary cause of severe lower respiratory tract infections in infants and young children.
  • RSV hospitalizations can significantly impair a child's quality of life (QoL).

Purpose of the Study:

  • To assess the impact of RSV hospitalization on the quality of life (QoL) in children under two years of age.
  • To quantify QoL loss, including utility and quality-adjusted life years (QALY) loss, associated with RSV infection.

Main Methods:

  • QoL was evaluated by parents/guardians using a 100-point visual analog scale.
  • Utility, QoL loss in days, and QALY loss were calculated and compared to a disease-free state.
  • 132 children aged 17 days to 24 months were included in the study.

Main Results:

  • Median utility during RSV hospitalization was 0.679, representing a loss of 0.321 utility points or 2.2 days.
  • The median QALY loss was 6.03 × 10-3, with pneumonia causing the highest loss (6.99 × 10-3).
  • QALY loss was not age-dependent, but utility scores showed a cumulative effect related to length of stay up to 13 days.

Conclusions:

  • RSV hospitalization leads to significant deterioration in utility and QALY loss in pediatric patients.
  • Patient-reported outcomes, including QoL measures, are crucial for pharmacoeconomic assessments of RSV's impact.
Abstract

Keywords:
bronchiolitisburdencaregivercost-effectivenesshealth-related quality of lifeinfantpneumoniaquality-adjusted life years (QALYs)respiratory syncytial virus

More Related Videos

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.9K
Use of a Video Scoring Anchor for Rapid Serial Assessment of Social Communication in Toddlers09:16

Use of a Video Scoring Anchor for Rapid Serial Assessment of Social Communication in Toddlers

Published on: March 14, 2018

10.3K

Related Concept Videos

Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
1.6K
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
2.5K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
253
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
263
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
353
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.1K